NRx Pharmaceuticals, Inc.
NRXP
$2.35
$0.083.48%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -13.19% | -16.86% | -3.82% | -5.02% | -28.12% |
| Depreciation & Amortization | 1,200.00% | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -24.44% | -39.24% | -27.73% | -28.58% | -38.08% |
| Operating Income | 25.63% | 39.24% | 27.73% | 28.58% | 38.08% |
| Income Before Tax | -86.76% | -36.16% | 5.96% | 16.66% | 43.48% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -86.76% | -36.16% | 5.96% | 16.66% | 43.48% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -86.76% | -36.16% | 5.96% | 16.66% | 43.48% |
| EBIT | 25.63% | 39.24% | 27.73% | 28.58% | 38.08% |
| EBITDA | 25.67% | 39.25% | 27.74% | 28.58% | 38.09% |
| EPS Basic | -6.81% | 20.27% | 38.37% | 42.43% | 57.64% |
| Normalized Basic EPS | 25.85% | 34.95% | 39.19% | 38.94% | 50.90% |
| EPS Diluted | -6.81% | 20.27% | 38.74% | 42.70% | 57.80% |
| Normalized Diluted EPS | 25.85% | 34.95% | 39.19% | 38.94% | 50.90% |
| Average Basic Shares Outstanding | 79.17% | 61.55% | 54.60% | 40.88% | 33.33% |
| Average Diluted Shares Outstanding | 79.17% | 61.55% | 54.60% | 40.88% | 33.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |